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The prevalence of hepatitis B virus (HBV) infection 
in patients with haematological malignancies is 
higher than that in the general population.[1] The 
higher prevalence can be explained by the immune 
suppression induced by cytotoxic chemotherapy, 
which leads to increased susceptibility.[2,3] Immune suppression may 
also lead to reactivation of occult HBV infection and increased HBV 
replication.
Horizontal transmission of HBV during early childhood is consid­
ered the main route of infection in developing countries.[4­9] This 
transmission of HBV is unrelated to sexual, perinatal or parenteral 
exposure. Transmission between family members may occur in 
communities with poor socioeconomic and hygienic conditions, and 
with long periods of close interaction.[10] The mode of horizontal 
transmission is uncertain, but contact with body fluids, mainly saliva, 
is a prominent feature.[7,8,11]
Vaccination is recommended for individuals at risk of HBV 
infection as a result of percutaneous or mucosal exposure to blood 
or blood products, as well as for those at risk of severe hepatitis B 
infection.[5] Patients in oncology units, transplant candidates, and 
individuals receiving frequent blood or blood product transfusions 
should be vaccinated.[1,5]
From April 1995, the HBV vaccine was included in the South 
African Expanded Programme of Immunisation (EPI­SA) at 6, 10 
and 14 weeks of age. No ‘catch­up’ immunisation of older age groups 
was implemented.[4] In 2010, 94% of children in South Africa (SA) 
were reported to be fully immunised against HBV (received three 
doses) in their first year of life.[6,8] However, according to the World 
Health Organization (WHO), only 56% of babies in SA received all 
three doses.[8] Current reports on children vaccinated against HBV 
in SA have found a low prevalence of hepatitis B surface antigen 
(HBsAg) positivity, ranging from none in children with unknown 
HIV status to 2.7% in HIV­positive children.[8,9]
The effectiveness of the HBV vaccine is assessed by measuring 
antibody levels to HBsAg (anti­HBs) levels in the serum. Various 
studies conducted after the inclusion of HBV vaccine in the EPI­
SA immunisation schedule have shown the vaccine to be highly 
immunogenic and effective.[8] Protective levels of anti­HBs, defined 
as >10 mIU/l in healthy, immune­competent children,[8] were found 
in 78 ­ 87% of healthy children, with none or very few children 
positive for HBsAg or HBV DNA. The vaccine was also tested 
in babies with HIV infection, in whom it has proved to be less 
effective. For example, protective levels of anti­HBs achieved through 
immunisation were found in 78.1% of HIV­positive patients in 
comparison with 85.7% of HIV­negative patients.[8]
The duration of HBV­vaccine­induced immunity after primary 
immunisation during infancy is not known.[12,13] Although specific 
antibody levels decline rapidly after vaccination, protection through 
immune memory is thought to extend into adulthood. The waning of 
vaccine­induced immunity could leave adolescents and adults at risk 
of HBV infection.[13]
Objective
This study reports on an audit of records of children presenting to 
a haematology and oncology unit. Our primary objective was to 
investigate serological evidence of previous exposure to HBV or 
vaccine immunity to HBV at first presentation. A secondary objective 
was to identify patients at risk of contracting hepatitis B infection 
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should also be given to offering booster vaccination to the population as a whole.
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through horizontal transmission. The overall 
aim of the study was to provide a basis on 
which a further preventive strategy could be 
developed if deemed necessary.
Methods
A hospital­based audit was done using patient 
records of all children who presented to the 
paediatric haematology and oncology unit 
at Steve Biko Academic Hospital (SBAH), 
a tertiary academic hospital in Pretoria, 
SA, during the period 1 January 2012 ­ 31 
December 2013. Demographic data (age and 
gender) and diagnosis of each patient were 
documented on presentation. HBV serology 
results for all patients (irrespective of the 
diagnosis) were reviewed.
Serological screening for hepatitis A, B 
and C is routinely done on all new patients 
on presentation to the unit. Screening for 
HBV includes serological testing for HBsAg, 
anti­HBs and antibodies to hepatitis B core 
antigen (anti­HBc). Hepatitis B e­antigen 
(HBeAg) and antibodies to hepatitis B 
e­antigen (anti­HBe) are only tested for when 
HBsAg is positive (in patients with hepa titis 
B infection). Immunoassays using Abbott 
ARCHITECT i2000 (Abbott Diagnostics, 
Germany) were used for HBV sero logical 
testing.
Anti­HBs levels of >100 mIU/ml were 
defined as complete protection against hep­
atitis B infection, levels of 10 ­ 100 mIU/ml as 
partial protection and levels of <10 mIU/ml as 
no protection. Antibody levels of >100 mIU/
ml are recommended for ensuring protection 
against hepatitis B infection in immune­
compromised patients.[14­17]
Data were analysed with SSPS version 
21. All proportions are reported as per­
centages with 95% confidence intervals 
(CIs). Differences between proportions were 
com pared using the χ2 test. A threshold 
of significance of p=0.05 was used for all 
analyses.
Results
A total of 210 patients who presented to 
our unit between 1 January 2012 and 31 
December 2013 were included. None had 
received previous immunosuppressive 
therapy. Table 1 summarises the diag noses 
and anthropometric data. Diagnoses were 
as follows: 41 (19.5%) leukaemia, 31 (14.8%) 
lymphoma (21 non­Hodgkin’s lymphoma, 
10 Hodgkin’s lymphoma), 92 (43.8%) solid 
tumours, and 46 (21.9%) benign or non­
malignant haematological conditions. 
The solid tumour group did not include 
any patients with primary liver tumours 
(hepatoma, hepatoblastoma or hepatocellular 
carcinoma). Of the 210 patients, 25 (11.9%) 
were HIV­infected, and of these eight (32.0%) 
were newly diagnosed on presentation to the 
unit. There were 130 boys and 80 girls in the 
study group. The median age of the study 
group as a whole was 6.5 years (range 3 
weeks ­ 17.6 years), that of the leukaemia/
lymphoma group 7.3 years (range 4 weeks ­ 
16.7 years), that of the solid tumour group 4.9 
years (range 3 weeks ­ 17.6 years), and that 
of the group with benign or non­malignant 
haematological conditions 7.9 years (range 3 
weeks ­ 15.7 years).
Active hepatitis B infection (HBsAg) was 
not detected in any of the patients during 
screening at the time of presentation to the 
unit. Six patients (2.9%) had evidence of 
previous infection with anti­HBc detected 
in serum, but no current active infection 
(HBsAg­negative). One of the six patients 
with evidence of previous infection was 
HIV­positive and not yet on antiretroviral 
treatment.
Of the 210 patients in the study, 84 (40.0%; 
95% CI 33.3 ­ 47.0) were sero negative for 
HBV, and 78 (37.1%; 95% CI 30.6 ­ 44.0) 
had anti­HBs titres of 10 ­ 100 mIU/ml, 
considered to be insufficient in a population 
of immune­compromised patients. Only 
48 patients (22.9%; 95% CI 17.4 ­ 29.2%) 
had anti­HBs titres >100 mIU/ml and were 
therefore protected against acquiring HBV 
(Fig. 1). Of the 25 HIV­positive patients, 20 
(80.0%; 95% CI 59.3 ­ 93.2) had no immun­
ity to HBV (anti­HBs titres <10 mIU/ml) 
(Fig. 2). There was a significant difference 
in immunity against HBV between the 1 ­ 
5­years age group and the over­12 age group 
Table 1. Diagnoses, gender and ages of children presenting to the paediatric haematology and oncology unit at SBAH (N=210)
Characteristic Leukaemia Lymphoma Solid tumours Haematological conditions* Other†
N (%) 41 (19.5) 31 (14.8) 92 (43.8) 24 (11.4) 22 (10.5)
Males, n (%) 24 (58.5) 26 (83.9) 51 (55.4) 17 (70.8) 12 (54.5)
Age (years) 
Median 5.8 10.3 4.9 7.9 6.7
Range 0.1 ­ 16.7 2.3 ­ 15.3 0.1 ­ 17.6 0.6 ­ 13.9 0.1 ­ 15.7
SBAH = Steve Biko Academic Hospital.
*Non­malignant haematological conditions include severe aplastic anaemia and sickle cell anaemia.




















Fig. 1. Hepatitis B immunity in the study group. (Protected = antibody levels to hepatitis B surface 
antigen (anti-HBs) >100 mIU/ml; insufficient immunity = anti-HBs 10 - 100 mIU/ml; not immune = 
anti-HBs <10 mIU/ml.)
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(p=0.005). In the age group 1 ­ 5 years, 26 
of 71 patients (36.6%; 95% CI 25.5  ­ 48.9) 
had sufficient immunity (anti­HBs titres 
>100  mIU/ml), while in the over­12 age 
group only four of 40 (10.0%; 95% CI 2.8  ­ 
23.7) did so. In the <1­year age group, 
five infants were <8 weeks of age and had 
therefore not received the first dose of HBV 
vaccine and had no protective immunity.
In the group with benign or non­
malignant haematological conditions, 12 of 
the 46 patients (26%; 95% CI 14.2 ­ 41.0) 
had anti­HBs levels of >100 mIU/ml, and in 
the leukaemia/lymphoma group only nine 
of 72 patients (12.5%; 95% CI 5.9 ­ 22.4) did 
so (Fig. 3).
Discussion
None of the patients in this study had active 
hepatitis B infection at initial screening 
and only six had evidence of previous 
infection. This rate of exposure to HBV is 
in keeping with the prevalence in SA (range 
0 ­ 2.7%) and reflects the protective effect 
of the immunisation received as part of the 
EPI­SA.
There were, however, a large number of 
patients (77.1%) in the study with sub­
optimal anti­HBs titres of <100 mIU/ml. 
While there is no consensus about what 
level of antibodies against HBV is pro­
tective in immune­compromised patients, 
it is accepted that a level of >10  mIU/ml 
after immunisation decreases the risk of 
a child with a normal immune response 
becoming a chronic carrier, despite the 
declining antibody level.[14­17] The immune 
memory capable of protecting against 
chronic or symptomatic hepatitis B 
infection persists even after antibody levels 
decline to <10 mIU/ml.[12] This immune 
memory has been shown to be protective 
in a large percentage of healthy children, 
but has not been assessed in patients on 
immunosuppressive therapy. The defects 
in immunological functioning caused by 
intensive chemotherapy may adversely 
affect the immune memory so that it may 
not be protective in childhood cancer 
patients.[18] Despite being vaccinated as part 
of the EPI­SA, patients have acquired HBV 
in the paediatric oncology unit at SBAH.[7]
Previous studies have shown that HBV 
immunity declines with age.[6,8,12,13] We were 
able to demonstrate a significant difference 
in levels of immunity to HBV in our patients. 
However, when comparing the 1 ­ 5­year 
age group with the over­12 group in this 
study, this difference in immunity may be 
overestimated when the size of the study 
population (N=210) is taken into account. It 
is not possible to comment on the decline of 
HBV immunity in the study patients, because 
their HBV serology was not repeated.
Factors that increase susceptibility to 
HBV infection and reactivation in paediatric 
oncology patients may include frequent 
prolonged hospital admissions, severe 
immune­compromised states, a need for 
frequent blood product administration, 
and destruction of mucous membranes 
following cytotoxic chemotherapy.[1,2] Active 
immunisation against HBV has been shown 
to be effective in patients with cancer.[3]
The role of passive immunisation using a 
specific immune globulin containing a high 
titre of anti­HBs (HBIG) in combination with 
hepatitis B vaccine has been well described 
in the setting of post­exposure prophylaxis 
following perinatal exposure for infants 
born to HBsAg­positive mothers.[19] HBIG 
is also used for protection against severe 
recurrent HBV infection in liver transplant 
patients.[19] The combination of intravenous 
HBIG with HBV vaccination in children 
with malignant diseases has been studied in 





















Fig. 3. Hepatitis B immunity in the subgroup of patients with leukaemia/lymphoma. (Protected = 
antibody levels to hepatitis B surface antigen (anti-HBs) >100 mIU/ml; insufficient immunity = anti-





















Fig. 2. Hepatitis B immunity in the subgroup of patients with HIV. (Protected = antibody levels to hepatitis 
B surface antigen (anti-HBs) >100 mIU/ml; insufficient immunity = anti-HBs 10 - 100 mIU/ml; not 
immune = anti-HBs <10 mIU/ml.)
RESEARCH
631       September 2014, Vol. 104, No. 9
combined passive­active immunisation offered better protection 
against nosocomial HBV infection than active immunisation 
alone. The cost implication of offering solely passive prophylaxis 
during intensive chemotherapy of patients with leukaemia and 
non­Hodgkin’s lymphoma led to discontinuation of this protocol 
and a recommendation for simultaneous passive and active 
immunoprophylaxis from the start of such therapy.[20]
HIV­positive patients in this study had very low levels of immunity 
to HBV. We could find no published reports on immunity to HBV 
of HIV­infected children compared with HIV­negative children. 
Among unimmunised adults, patients with AIDS were reported to 
have significantly decreased anti­HBs titres compared with a control 
group of HIV­negative adults.[22] Adults with HBV/HIV co­infection 
have significantly higher HBV viral loads and for this reason are 
highly infectious, with an increased risk of transmitting HBV to close 
contacts and susceptible health workers.[22] This is especially relevant 
and dangerous in a paediatric haematology and oncology unit where 
patients are continuously in close contact with each other and where 
there have been previous reports of HBV transmission.[7] Patients 
with underlying HIV disease at the time of cancer diagnosis should 
be given combined passive­active immunisation to offer the best 
possible protection against HBV infection.[23]
Acute hepatitis infection caused by HBV could lead to delays 
in chemotherapy and for this reason worsen the patient’s cancer­
related prognosis.[1] Most children infected with HBV develop 
chronic hepatitis and therefore have an increased risk of developing 
cirrhosis and hepatocellular carcinoma.[3] The complications of 
chronic hepatitis could potentially have a detrimental effect on the 
long­term morbidity of this group of patients.
Conclusion
A large group of patients attending our paediatric haematology 
and oncology unit did not have sufficient protective antibodies 
against HBV at first presentation, despite being vaccinated 
as part of the EPI­SA. These patients are at risk of hepatitis 
B infection. Active surveillance and continued screening for 
HBV must be done at first presentation of all patients attending 
a paediatric haema tology and oncology unit, and regularly 
during treatment and follow­up. A programme to immunise all 
seronegative patients against HBV should be implemented, and 
the response to immunisation documented. The use of combined 
passive­active immunisation should be encouraged, especially 
in children with haematological malignancies and HIV­infected 
children. Implementation of an effective screening and vaccination 
programme in the haematology and oncology unit should protect 
all patients from contracting HBV.
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